---
permalink: /publications/
title: "Published work"
excerpt: "Publications and pre-prints."
toc: false
# Header
header:
  overlay_image: /assets/img/collateraldesign.jpg
  overlay_filter: linear-gradient(135deg, rgba(135, 206, 235, 0.5), rgba(255, 255, 255, 0.5))
  show_overlay_excerpt: false
  image_description: "A plot of GP consultations over COVID-19 lockdown"
  
---
## Full details available at
[ORCiD](https://orcid.org/0000-0002-8903-4906)

[Google Scholar](https://scholar.google.com/citations?user=FQrBtfAAAAAJ&hl=en&authuser=1)

## Selected publications
### University of Glasgow
* Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, **Henderson AD**, Lam CSP, Pitt B, Senni M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. 2024. _New England Journal of Medicine_ 391(16):1475-1485.
* Jhund PS, Talebi A, **Henderson AD**, Claggett BL, Vaduganathan M, Desai AS, Lam CSP, Pitt B, Senni M, Shah SJ, et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. 2024. _The Lancet_ 404(10458):1119-1131.
* Kondo T, **Henderson AD**, Docherty KF, Jhund PS, Vaduganathan M, Solomon SD, McMurray JJV. Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF? 2024. _Journal of the American College of Cardiology_.
* Docherty KF, **Henderson AD**, Jhund PS, Claggett BL, Desai AS, Mueller K, Viswanathan P, Scalise A, Lam CSP, Senni M, et al. Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial. 2024. _Circulation_.
* Yang M, **Henderson AD**, Talebi A, Atherton JJ, Chiang CE, Chopra V, Comin-Colet J, Kosiborod MN, Saraiva JF, Claggett BL, et al. Effect of finerenone on the KCCQ in patients with HFmrEF/HFpEF: A prespecified analysis of FINEARTS-HF. 2024. _Journal of the American College of Cardiology_.

### LSHTM
* **Henderson AD**, Butler-Cole BFC, Tazare J, Tomlinson LA, Marks M, Jit M, Briggs A, Lin L-Y, Carlile O, Bates C, et al. Clinical coding of long COVID in primary care 2020--2023 in a cohort of 19 million adults: an OpenSAFELY analysis. 2024. _EClinicalMedicine_ 72.
* Tazare J, **Henderson AD**, Morley J, Blake HA, McDonald H, Williamson E, Strongman H. NHS National Data Opt-Outs: trends and potential consequences for health data research. 2024. _BJGP open_.
* Carlile O, Briggs A, **Henderson AD**, Butler-Cole BFC, Tazare J, Tomlinson LA, Marks M, Jit M, Lin L-Y, Bates C, et al. Impact of long COVID on health-related quality-of-life: an OpenSAFELY population cohort study using patient-reported outcome measures (OpenPROMPT). 2024. _The Lancet Regional Health--Europe_ 40.
* Matthewman J, Mulick A, Dand N, Major-Smith D, **Henderson AD**, Pearce N, Denaxas S, Iskandar R, Roberts A, Cornish RP, et al. Disagreement concerning atopic dermatitis subtypes between an English prospective cohort (ALSPAC) and linked electronic health records. 2024. _Clinical and Experimental Dermatology_ llae196.
* **Henderson AD**, Adesanya E, Mulick A, Matthewman J, Vu N, Davies F, Smith CH, Hayes J, Mansfield KE, Langan SM. Common mental health disorders in adults with inflammatory skin conditions: nationwide population-based matched cohort studies in the UK. 2023. _BMC Medicine_ 21(1):285.
* Mansfield KE, Mathur R, Tazare J, **Henderson AD**, Mulick AR, Carreira H, Matthews AA, Bidulka P, Gayle A, Forbes H, et al. Indirect acute effects of the COVID-19 pandemic on physical and mental health in the UK: a population-based study. 2021. _The Lancet Digital Health_ 3(4):e217-e230.

### PhD
* **Henderson AD**; Kama M; Aubry M; Hue S; Teissier A; Naivalu T; Bechu VD; Kailawadoko J; Rabukawaqa I; Sahukhan A [Interactions between timing and transmissibility explain diverse flavivirus dynamics in Fiji.](https://doi.org/10.1038/s41467-021-21788-y) 2021 _Nature communications_
* **Henderson AD**; Aubry M; Kama M; Vanhomwegen J; Teissier A; Mariteragi-Helle T; Paoaafaite T; Teissier Y; Manuguerra J-C; Edmunds J [Zika seroprevalence declines and neutralizing antibodies wane in adults following outbreaks in French Polynesia and Fiji.](https://doi.org/10.7554/eLife.48460) 2020 _eLife_
*  Aubry M; Kama M; **Henderson AD**; Teissier A; Vanhomwegen J; Mariteragi-Helle T; Paoaafaite T; Manuguerra J-C; Christi K; Watson CH [Low chikungunya virus seroprevalence two years after emergence in Fiji.](https://doi.org/10.1016/j.ijid.2019.10.040) 2019 _International Journal of Infectious Diseases_
* **Henderson A**; Iwagami M; Bottomley C; Tomlinson L; Mansfield K; Nitsch D [Paediatric acute kidney injury hospital admissions in England 1997-2014: burden and risk factors.](https://doi.org/10.1093/ckj/sfz075) 2019 _Clinical kidney journal_

## Opinion article and podcast
* Indirect effects of the pandemic on UK health [LSHTM website](https://www.lshtm.ac.uk/newsevents/expert-opinion/indirect-effects-pandemic-uk-health)
* How long does Zika immunity last for? [eLife podcast episode 63](https://elifesciences.org/podcast/episode63#962) 

## Shiny apps
* COVID-Collateral [shiny app](https://a-henderson91.shinyapps.io/covid_collateral_shiny/)

